A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO study

Arthritis and Rheumatism

Volumn 52, Issue 5, 2005, Pages 1360-1370

  Lehman, Allen J ^a   Esdaile, John M ^a,e   Klinkhoff, Alice V ^a   Grant, Eric ^b   Fitzgerald, Avril ^c   Canvin, Janice ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b St John Regional Hospital   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOGLUCOSE; CORTICOSTEROID; GOLD; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STEROID;

ABDOMINAL PAIN; ADULT; AGED; AMERICAN COLLEGE OF RHEUMATOLOGY SCORE; ARTICLE; BUTTOCK; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUGHING; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MIXTURE; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEALTH CARE COST; HUMAN; LEUKOPENIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MOUTH ULCER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SKIN TUMOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TASTE DISORDER; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GOLD; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; METHOTREXATE; MIDDLE AGED; TIME FACTORS;

EID: 18644373869     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21018     Document Type: Article

References (51)

1. Hochberg MC, Spector TD. Epidemiology of rheumatoid arthritis: update. Epidemiol Rev 1990;12:247-52.
2. Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997;24:1051-60.
3. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24:719-25.
4. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997;24:43-8.
5. O'Dell, JR. Methotrexate use in rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:779-96.
6. O'Dell J. Conventional DMARD options for patients with a suboptimal response to methotrexate. J Rheumatol Suppl 2001;62:21-6.
7. Gordon DA, Klinkhoff AV. Gold and penicillamine. In: Ruddy S, Sledge CB, editors. Kelley's textbook of rheumatology. Philadelphia: WB Saunders; 2001. p. 869-78.
8. Pope JE, Hong P, Koehler BE. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. J Rheumatol 2002;29:255-60.
9. Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol 1998;25:2331-8.
10. Sokka T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;29:2521-4.
11. Iannuzzi L, Dawson N, Zein N, Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med 1983;309:1023-8.
12. Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997;36:345-52.
13. Blanco-Rodriquez J, Insua-Vilarino SA, Bretal-Laranga MC, Caamano-Freire M, Mera-Varela AJ, Romero-Yuste S, et al. The comparative study of toxicity, efficacy and survival of combination therapy with gold plus MTX versus monotherapy in RA patients in northwest of Spain [abstract]. Arthritis Rheum 1994;37 Suppl 9:S254.
14. Rau R. Combination DMARD treatment with parenteral gold and methotrexate. Clin Exp Rheumatol 1999;17:S83-90.
15. Elkayam O, Yaron M, Zhukovsky G, Segal R, Caspi D. Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. Rheumatol Int 1997;17:49-53.
16. Marcus RE, Sebba A. Comparison of efficacy and toxicity of single and combination DMARD therapy in 263 patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1994;37 Suppl 6:R39.
17. Brawer AE. The combined use of oral methotrexate and intramuscular gold in rheumatoid arthritis [abstract]. Arthritis Rheum 1988;31 Suppl 1:R10.
18. Rau R, Karger T. The European experience. In: Wilke WS, editor. Methotrexate therapy in rheumatic disease. New York: Marcel Dekker; 1989. p. 57-90.
19. Felipe E, Becerra MD. The combined use of intramuscular gold (GSTM) and oral bolus of methotrexate (MTX) versus GSTM in rheumatoid arthritis (RA): an open, randomized and comparative study [abstract]. Proceedings of the Congress of the International League of Associations for Rheumatology; 1989. p. 658.
20. Lehman AJ, Lacaille D, Nair B, Stein HB, Klinkhoff AV, Esdaile JM. Intramuscular gold and methotrexate combination therapy in rheumatoid arthritis [abstract]. Arthritis Rheum 1998;41 Suppl 9:S59.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Liang MH, Fries JF. Containing costs in chronic disease: monitoring strategies in the gold therapy of rheumatoid arthritis. J Rheumatol 1978;5:241-4.
23. Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
24. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med 1995;98:156-68.
25. Klinkhoff AV, Bellamy N, Bombardier C, Carette S, Chalmers A, Esdaile JM, et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988;15:492-4.
26. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
27. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
28. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
29. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
30. Clarke AE, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol 1999;26:1500-11.
31. Clarke AE, Esdaile JM, Bloch DA, Lacaille D, Danoff DS, Fries JF. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993;36:1548-59.
32. Gironimi G, Clarke AE, Hamilton VH, Danoff DS, Bloch DA, Fries JF, et al. Why health care costs more in the US; comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal. Arthritis Rheum 1996;39:979-87.
33. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990;6:57-75.
34. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982;60:429-62.
35. Baladi JF. A guidance document for the costing process. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1996.
36. Database NH. National health expenditure trends, 1975-2001. Ottawa: Canadian Institute for Health Information; 2001.
37. DAD resource intensity weights and expected length of stay. Ottawa: Canadian Institute for Health Information; 2002.
38. Hospital indicators, 1993-1994. Ottawa: Statistics Canada 83-246-XMB; 1996.
39. A national list of provincial costs for health care: Canada 1997-98. Edmonton: Institute of Health Economics; 1998.
40. Clarke AE, Penrod J, St. Pierre Y, Petri MA, Manzi S, Isenberg DA, et al, and the Tri-Nation Study Group. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. J Rheumatol 2000;27:2597-604.
41. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al, and The Methotrexate-Cyclosporine Combination Study Group. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
42. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
43. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/ toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
44. Klinkhoff AV, Teufel A. Reinstitution of gold after gold induced proteinuria. J Rheumatol 1997;24:1277-9.
45. Klinkhoff AV, Teufel A. How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions. J Rheumatol 1995;22:1657-9.
46. McKenzie JM. Report on a double-blind trial comparing small and large doses of gold in the treatment of rheumatoid disease. Rheumatol Rehabil 1981;20:198-202.
47. Cheatum DE. How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions [letter]. J Rheumatol 1996;23:944.
48. Lockie LM, Smith DM. Forty-seven years experience with gold therapy in 1,019 rheumatoid arthritis patients. Semin Arthritis Rheum 1985;14:238-46.
49. Klinkhoff AV, Teufel A, McCartney C. A review of 38 years of experience with injectible gold [abstract]. Clin Invest Med 1989;12:B95.
50. Van Gestel A, Koopman R, Wijnands M, van de Putte L, van Riel P. Mucocutaneous reactions to gold: a prospective study of 74 patients with rheumatoid arthritis. J Rheumatol 1994;21:1814-9.
51. Klinefelter. Reinstitution of gold therapy in rheumatoid arthritis after mucocutaneous reactions. J Rheumatol 1975;2:21-7.